Table 1.
Summary of preclinical tumor models evaluating the combination of PS-targeting antibodies with chemotherapy or radiation
| Tumor name | Tumor type | PS-targeting antibody/dose regimen | TGI/survival/ regression PS targeting | Chemotherapy or radiation | TGI/survival/regression chemotherapy or radiation | TGI/survival/regression combination | Reference |
|---|---|---|---|---|---|---|---|
| MiaPaca-2, Pan02 | Human pancreatic | 3G4 | MiaPaca-2, 31% TGI; Pan02, 36% TGI | Gemcitabine | MiaPaca-2, 48% TGI; Pan02, 40% TGI | MiaPaca-2, 69% TGI; Pan02, 61% TGI | Beck et al (2005)66 |
| F98 | Rat glioma | 2aG4 | 0% survival | Radiation 10 Gy | 0% survival | 13% survival | He et al (2009)69 |
| A549, H460 | Human lung | 2aG4 or 3G4, 100 µg, tiw ×3 | 41% TGI; 73% TGI | Radiation, 2 Gy ×5 days | 14% TGI; 80% TGI | 80% TGI; >99% TGI | He et al (2007)68 |
| MDA-MB-435 | Human breast | 3G4, 100 µg, biw | 50% TGI | Docetaxel, 10 mg/kg, biw | 70% TGI | 93% TGI | Huang et al (2005)65 |
| BT-474, HCC-1428 | Human breast | 2aG4, 100 µg, tiw ×4 | BT474, 30% TGI, 5.6% reg; HCC-1428, 40.4% TGI | Prima-1, 50–75 mg/kg, 100 µg, tiw ×3 | BT474, 50% TGI, 11.1% reg; HCC-1428, 43.5% TGI | BT474, 75% TGI, 27.8% reg; HCC-1428, 66% TGI | Liang et al (2010)71 |
| MDA-MB-435 | Human breast | 3G4, 100 µg, biw | 65% TGI | – | – | – | Ran et al (2005)61 |
| Meth A | Mouse fibrosarcoma | 3G4, 100 µg, biw | 90% TGI | – | – | – | Ran et al (2005)61 |
| MDA-MB-231 | Human breast | 3G4, 100 µg, biw | 75% TGI | – | – | – | Ran et al (2005)61 |
| L540cy | Hodgkin’s lymphoma | 3G4, 100 µg, biw | 50% TGI | – | – | – | Ran et al (2005)61 |
| PC3 | Human prostate | 2aG4, 4 mg/kg, biw | ~30% | Docetaxel, 5 mg/kg, biw | ~14% | >95% | Yin et al (2013)32 |
| TRAMP | Mouse prostate GEMM | mch1N11, 5 mg/ kg, biw | 0% survival | Castration | 0% survival | ~50% survival | Yin et al (2012)115 |
Notes: Preclinical models were conducted in immunocompetent or immune-deficient animals with antibodies 3G4, 2aG4, or mch1N11. TGI was determined based on percent inhibition of treatment group compared to control for either the last day of measurement or when animals reached tumor volume limit.
Abbreviations: biw, two times weekly; GEMM, genetically engineered mouse model; PS, phosphatidylserine; TGI, tumor growth inhibition; tiw, three times weekly.